Literature DB >> 11325961

The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein.

N Settasatian1, M Duong, L K Curtiss, C Ehnholm, M Jauhiainen, J Huuskonen, K A Rye.   

Abstract

Phospholipid transfer protein (PLTP) remodels high density lipoproteins (HDL) into large and small particles. It also mediates the dissociation of lipid-poor or lipid-free apolipoprotein A-I (apoA-I) from HDL. Remodeling is enhanced markedly in triglyceride (TG)-enriched HDL (Rye, K.-A., Jauhiainen, M., Barter, P. J., and Ehnholm. C. (1998) J. Lipid. Res. 39, 613-622). This study defines the mechanism of the remodeling of HDL by PLTP and determines why it is enhanced in TG-enriched HDL. Homogeneous populations of spherical reconstituted HDL (rHDL) containing apoA-I and either cholesteryl esters only (CE-rHDL; diameter 9.3 nm) or CE and TG in their core (TG-rHDL; diameter 9.5 nm) were used. After 24 h of incubation with PLTP, all of the TG-rHDL, but only a proportion of the CE-rHDL, were converted into large (11.3-nm diameter) and small (7.7-nm diameter) particles. Only small particles were formed during the first 6 h of incubation of CE-rHDL with PLTP. The large particles and dissociated apoA-I were apparent after 12 h. In the case of TG-rHDL, small particles appeared after 1 h of incubation, while dissociated apoA-I and large particles were apparent at 3 h. The composition of the large particles indicated that they were derived from a fusion product. Spectroscopic studies indicated that the apoA-I in TG-rHDL was less stable than the apoA-I in CE-rHDL. In conclusion, these results show that (i) PLTP mediates rHDL fusion, (ii) the fusion product rearranges by two independent processes into small and large particles, and (iii) the more rapid remodeling of TG-rHDL by PLTP may be due to the destabilization of apoA-I.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325961     DOI: 10.1074/jbc.M010708200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.

Authors:  Barry I Freedman; Carl D Langefeld; Mariana Murea; Lijun Ma; James D Otvos; Jolyn Turner; Peter A Antinozzi; Jasmin Divers; Pamela J Hicks; Donald W Bowden; Michael V Rocco; John S Parks
Journal:  Nephrol Dial Transplant       Date:  2011-09-19       Impact factor: 5.992

2.  Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus.

Authors:  R de Vries; G M Dallinga-Thie; A J Smit; B H R Wolffenbuttel; A van Tol; R P F Dullaart
Journal:  Diabetologia       Date:  2005-12-23       Impact factor: 10.122

Review 3.  The metabolism and anti-atherogenic properties of HDL.

Authors:  Kerry-Anne Rye; Christina A Bursill; Gilles Lambert; Fatiha Tabet; Philip J Barter
Journal:  J Lipid Res       Date:  2008-11-24       Impact factor: 5.922

4.  Structural basis of the lipid transfer mechanism of phospholipid transfer protein (PLTP).

Authors:  Meng Zhang; Xiaobo Zhai; Jinping Li; John J Albers; Simona Vuletic; Gang Ren
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-06-05       Impact factor: 4.698

5.  PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity.

Authors:  Daniel Seung Kim; Amber A Burt; Jane E Ranchalis; Simona Vuletic; Tomas Vaisar; Wan-Fen Li; Elisabeth A Rosenthal; Weijiang Dong; Jason F Eintracht; Arno G Motulsky; John D Brunzell; John J Albers; Clement E Furlong; Gail P Jarvik
Journal:  J Lipid Res       Date:  2015-05-25       Impact factor: 5.922

Review 6.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

7.  Linkage and association of phospholipid transfer protein activity to LASS4.

Authors:  Elisabeth A Rosenthal; James Ronald; Joseph Rothstein; Ramakrishnan Rajagopalan; Jane Ranchalis; G Wolfbauer; John J Albers; John D Brunzell; Arno G Motulsky; Mark J Rieder; Deborah A Nickerson; Ellen M Wijsman; Gail P Jarvik
Journal:  J Lipid Res       Date:  2011-07-13       Impact factor: 5.922

Review 8.  Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism.

Authors:  Henry J Pownall; Corina Rosales; Baiba K Gillard; Mauro Ferrari
Journal:  Methodist Debakey Cardiovasc J       Date:  2016-09

9.  Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD).

Authors:  Madeleine V Pahl; Zhenmin Ni; Lili Sepassi; Hamid Moradi; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2009-03-18       Impact factor: 5.992

Review 10.  Lipoproteins, cholesterol homeostasis and cardiac health.

Authors:  Tyler F Daniels; Karen M Killinger; Jennifer J Michal; Raymond W Wright; Zhihua Jiang
Journal:  Int J Biol Sci       Date:  2009-06-29       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.